Close Menu

Siemens

The firm has launched a multiplex real-time PCR assay that detects HPV 16, HPV 18, and a pool of 12 other high-risk HPV subtypes.

The firm aims to have its test on the European clinical market by early next year, followed by a launch in the US.

The university's researchers have developed a laboratory test that measures the body's response to infection in the blood, and can distinguish between bacterial and viral meningitis.  

The listing will allow Siemens Healthineers to invest in high-growth health sectors, such as molecular diagnostics, and to acquire US-based healthcare technology startups.

Among companies whose tests were greenlighted by the FDA last month, Quidel received clearances for a test to detect and differentiate influenza types A and B, and for a separate test for Lyme disease.

Siemens plans to offer 150 million shares, including 19.6 million shares to cover any overallotment, at between €26 to €31 per share.

Siemens disclosed its plans for the IPO last month. It said on Monday that as an independent company, Siemens Healthineers will have greater entrepreneurial flexibility.

The two tests will be added to the firm's menu of blood analysis assays, available on its newly-acquired handheld Epoc system.

The three firms each had 510(k) clearances for multiple products from the FDA last month for marketing.

The company recorded €13.8 billion in revenues in fiscal 2017, including €4.2 billion in diagnostics, €8.2 billion in imaging, and €1.5 billion in advanced therapies. 

Pages